Immune checkpoint inhibitors (ICIs) have revolutionized treatment for advanced solid tumors, but challenges like resistance and limited response rates persist. Learn how antibody arrays are showing great potential for advancing precision medicine in ICI therapy by enabling biomarker-based personalization, in our latest blog post with RayBiotech: https://lnkd.in/gGsASssu
